TY - JOUR T1 - Combination therapy with ciclosporin and etanercept in patients with psoriatic arthritis JF - Annals of the Rheumatic Diseases JO - Ann Rheum Dis SP - 934 LP - 935 DO - 10.1136/ard.2009.119446 VL - 69 IS - 5 AU - Salvatore D'Angelo AU - Maria Stefania Cutro AU - Ennio Lubrano AU - Pietro Leccese AU - Gianna Angela Mennillo AU - Nicola Ferrara AU - Ignazio Olivieri Y1 - 2010/05/01 UR - http://ard.bmj.com/content/69/5/934.abstract N2 - Psoriatic arthritis (PsA) is a heterogeneous disease involving the musculoskeletal structures, the skin and nails.1 2 Traditional disease-modifying antirheumatic drugs and tumour necrosis factor β (TNFβ) antagonists are effective on cutaneous and articular manifestations of psoriatic disease.3 4Most patients with PsA are successfully treated with TNFβ antagonists. However, a subset of patients with PsA are not responsive to these treatments or do not maintain a clinical response to the cutaneous manifestations despite the remission of arthritis.5The primary objective of this study was to evaluate the safety and efficacy of adding ciclosporin A (CsA) to etanercept in patients with PsA demonstrating an unsatisfactory control of cutaneous … ER -